Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
PT-141 is an early research designation for bremelanotide, a cyclic melanocortin receptor agonist. A specific pharmaceutical formulation is FDA-approved in the United States, but that approval does not transfer to research material or establish UK authorisation.
Key points
- The compound is a cyclic heptapeptide melanocortin receptor agonist developed from melanotan-II research.
- Evidence from cells, animals and humans must be interpreted separately.
- A bremelanotide medicine is FDA-approved in the US for a restricted indication. No equivalent inference should be made about UK research material; check the MHRA products database.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
PT-141 is an early research designation for bremelanotide, a cyclic melanocortin receptor agonist. A specific pharmaceutical formulation is FDA-approved in the United States, but that approval does not transfer to research material or establish UK authorisation. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
Bremelanotide acts centrally through melanocortin receptors, although the precise pathway underlying clinical effects remains incompletely defined.
What does the current evidence show?
- Two Phase 3 RECONNECT trials studied a defined 1.75 mg pharmaceutical product in premenopausal women with acquired, generalised hypoactive sexual desire disorder.
- The FDA approved Vyleesi in 2019 for that narrow indication and population, with important warnings and limitations.
- Earlier small studies examined melanocortin effects in other populations; these should not be combined indiscriminately with the Phase 3 evidence.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Approval applies to a specific manufacturer, formulation, indication and jurisdiction.
- Trial endpoints showed modest mean differences and require contextual interpretation.
- Findings cannot establish identity, safety or efficacy of independently supplied PT-141 research material.
Regulatory and safety context
A bremelanotide medicine is FDA-approved in the US for a restricted indication. No equivalent inference should be made about UK research material; check the MHRA products database. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.